Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 2/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15443881 | 0.84 | NPSR1 (0.56) | MCHR1ALDH1A1CYP2C19KMT2A | |
| SCHEMBL15443854 | 0.83 | DRD2 (0.55) | RAB9AHPGDSMN1; SMN2CTDSP1LMNA | |
| SCHEMBL16209871 | 0.81 | GRM5 (0.53) | RAB9AGRM5MCHR1ADRA2AALDH1A1 | |
| SCHEMBL18993488 | 0.81 | GRM5 (0.43) | RAB9AHPGDSMN1; SMN2GRM5MCHR1 | |
| SCHEMBL23347873 | 0.80 | GRM5 (0.41) | RAB9AHPGDSMN1; SMN2GRM5MCHR1 | |
| SCHEMBL16222336 | 0.80 | L3MBTL1 (0.56) | RAB9AGRM5MCHR1ADRA2AALDH1A1 | |
| SCHEMBL15443868 | 0.80 | DRD2 (0.47) | RAB9AHPGDSMN1; SMN2MCHR1CTDSP1 | |
| SCHEMBL14655021 | 0.79 | ALDH1A1 (0.49) | RAB9AHPGDSMN1; SMN2MCHR1LMNA | |
| SCHEMBL20031999 | 0.79 | SSTR4 (0.42) | RAB9AHPGDSMN1; SMN2GRM5MCHR1 | |
| SCHEMBL16219470 | 0.77 | GRM5 (0.51) | RAB9AHPGDSMN1; SMN2GRM5MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788487-B1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS INC (US) | 2018-04-04 | — | — | EP | disclosed |
| EP-2788488-B1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9682097-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9326992-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20140024698-A1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| WO-2013012752-A2 | METHODS AND COMPOSITIONS FOR MANIPULATING TRANSLATION OF PROTEIN ISOFORMS FROM ALTERNATIVE INITIATION START SITES | SAREPTA THERAPEUTICS, INC. (US) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024698-A1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNA, LMNB2, LMNB1 | RAB9A 3403/4885HPGD 2571/4885SMN1; SMN2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.